Statistical Design and Analysis of a Non-Inferiority Clinical Trial- BioMimics 3D Vascular Stent

Áine Glynn, Filip Kłosowski1

1 School of Mathematical and Statistical Sciences, University of Galway

Background and Problem

Objectives of Project

  1. To define and justify a non-inferiority margin for a BioMimics 3D stent using historical and published evidence.
  2. To develop statistically appropriate non-inferiority trial design parameters from a bio statistical perspective.
  3. Develop a Shiny app to determine and visualize different sample size requirements under varying design assumptions and inferiority margins.
  4. To analyse and interpret simulated trial data and evaluate non-inferiority conclusions.
  5. To critically reflect on the limitations and assumptions inherent to non-inferiority designs.

Definitions

Case-study: Biomimics 3D stent

what is it x x xx x x x x

Meta-analysis

maybe include image of plot?

continued

Margin-Jinn

Margin-Jinn is an interactive Shiny application developed as part of this project in order to support the statistical planning of non-inferiority clinical trials. The application enables visual exploration of sample size requirements across several different design parameters. Through dynamic plots and real-time updates, the app highlights the sensitivity of sample size modelling assumptions that are often fixed or under-examined during trial planning.

In our project Margin-Jinn is applied to the BioMimics 3D vascular stent to explore, justify and critically assess sample size choices under realistic design scenarios, reflecting the role of statistical decision-making in early-stage clinical trial design.

https://github.com/FilipMKgit/Margin-Jinn

Next Project Steps

  • Extend the BioMimics 3D case-study through simulation of non-inferiority trial data under realistic design assumptions.
  • Analyse simulated trial outcomes to assess non-inferiority conclusions for the proposed stent design.
  • Further explore the assumptions, limitations, and interpretational caveats inherent to non-inferiority clinical trials.

References